Literature DB >> 27939487

Cerebrospinal fluid levels of tau and phospho-tau-181 proteins during pregnancy.

Wolfgang Lederer1, Cristina Alomar Dominguez2, Marina Popovscaia3, Günther Putz2, Christian Humpel4.   

Abstract

OBJECTIVES: During pregnancy various interactions occur between structural alterations of the maternal brain and placental metabolism. The aim of the present study was to investigate whether cerebrospinal fluid concentrations of tau and phospho-tau-181 protein vary during normal pregnancy and in women with preeclampsia and HELLP syndrome. STUDY
DESIGN: We measured cerebrospinal fluid biomarkers, tau and phospho-tau-181 protein levels in 90 pregnant women electively assigned for regional anaesthesia during pregnancy or for cesarean section using enzyme-linked immunosorbent assays.
RESULTS: Cerebrospinal fluid concentrations for tau and phospho-tau-181 in 66 women with normal pregnancy were 308.5±117.3pg/mL and 50.5±16.7pg/mL, respectively. Blood pressure, liver function, clotting activity and kidney function were significantly different in eleven women with preeclampsia and HELLP syndrome. The weight of the newly born (p<0.001; HR: 0.998), the weight of the placenta (p=0.018) and concentrations for phospho-tau-181 (p=0.043; HR: 1.211) correlated significantly with the disease.
CONCLUSION: Mean concentrations of cerebrospinal fluid tau and phospho-tau-181 protein during pregnancy were evaluated. Phospho-tau-181 protein concentrations correlated with placental function supporting the hypothesis that altered expression of neuronal factors during pregnancy may affect development of the placenta.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Cerebrospinal fluid proteins; Placenta; Pregnancy preeclampsia; Tau protein function

Mesh:

Substances:

Year:  2016        PMID: 27939487     DOI: 10.1016/j.preghy.2016.08.243

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  4 in total

1.  Signs of neuroaxonal injury in preeclampsia-A case control study.

Authors:  Malin Andersson; Jonatan Oras; Sven Egron Thörn; Ove Karlsson; Peter Kälebo; Henrik Zetterberg; Kaj Blennow; Lina Bergman
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

2.  Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer's disease.

Authors:  Josef Marksteiner; Michaela Defrancesco; Christian Humpel
Journal:  Front Aging Neurosci       Date:  2022-09-29       Impact factor: 5.702

3.  Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study.

Authors:  Lina Bergman; Henrik Zetterberg; Helena Kaihola; Henrik Hagberg; Kaj Blennow; Helena Åkerud
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

4.  Beta-amyloid peptides(1-42) and (1-40) in the cerebrospinal fluid during pregnancy: a prospective observational study.

Authors:  Cristina Alomar-Dominguez; L Dostal; J Thaler; G Putz; C Humpel; W Lederer
Journal:  Arch Womens Ment Health       Date:  2020-10-02       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.